Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.
| العنوان: | Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Khaity A; Faculty of Medicine, Elrazi University, Khartoum, Sudan., Mostafa Al-Dardery N; Faculty of Medicine, Fayoum University, Fayoum, Egypt., Albakri K; Faculty of Medicine, The Hashemite University, Zarqa, Jordan., Abdelwahab OA; Faculty of Medicine, Al-Azhar University, Cairo, Egypt., Hefnawy MT; Faculty of Medicine, Zagazig University, Zagazig, Egypt., Yousef YAS; Faculty of Medicine, Elrazi University, Khartoum, Sudan., Taha RE; Faculty of Medicine, Khartoum University, Khartoum, Sudan., Swed S; Faculty of Medicine, Aleppo University, Aleppo, Syria., Hafez W; NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates.; Medical Research Division, Department of Internal Medicine, The National Research Centre, Cairo, Egypt., Hurlemann R; Department of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.; Department of Psychiatry, University Hospital Bonn, Bonn, Germany.; Research Center Neurosensory Science, Carl von Ossietzky University Oldenburg, Oldenburg, Germany., Elsayed MEG; Department of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.; Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany. |
| المصدر: | Frontiers in psychiatry [Front Psychiatry] 2023 May 05; Vol. 14, pp. 1153648. Date of Electronic Publication: 2023 May 05 (Print Publication: 2023). |
| نوع المنشور: | Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Switzerland : Frontiers Research Foundation, 2010- |
| مستخلص: | Aims: We performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia. Methods: We searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4). Results: Pooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,-4.46), P < 0.00001], waist circumference [MD = - 3.66, 95% CI (-3.89,-3.44), P < 0.00001], body mass index (BMI) [MD = - 1.09, 95% CI (-1.25,-0.93), P < 0.00001], systolic blood pressure (SBP) [MD = - 3.07, 95% CI (-3.61,-2.53), P < 0.00001], and diastolic blood pressure (DBP) [MD = - 2.02, 95% CI (-2.42,-1.62), P < 0.00001]. The total effect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), p = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), p = 0.28]; respectively}. Conclusion: Our analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy of GLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended. Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022333040. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Khaity, Mostafa Al-dardery, Albakri, Abdelwahab, Hefnawy, Yousef, Taha, Swed, Hafez, Hurlemann and Elsayed.) |
| References: | Postgrad Med. 2015;127(8):818-26. (PMID: 26371721) Mol Metab. 2021 Apr;46:101102. (PMID: 33068776) Diabetes Obes Metab. 2018 Apr;20(4):1050-1055. (PMID: 29194917) Clin Pharmacokinet. 2011 Jan;50(1):65-74. (PMID: 21142268) Schizophr Res. 2011 Mar;126(1-3):124-31. (PMID: 21159492) J Diabetes Investig. 2022 Jun;13(6):975-985. (PMID: 35112504) Lancet. 2018 Nov 24;392(10161):2269-2279. (PMID: 30293771) Psychiatriki. 2018 Jan-Mar;29(1):64-73. (PMID: 29754122) JAMA. 2012 Sep 19;308(11):1150-9. (PMID: 22990274) Psychiatry Res. 2021 Feb;296:113670. (PMID: 33373806) Recent Pat CNS Drug Discov. 2010 Jun;5(2):109-17. (PMID: 20337586) N Engl J Med. 2010 Sep 2;363(10):905-17. (PMID: 20818901) Eur J Pharmacol. 2010 Mar 25;630(1-3):158-62. (PMID: 20035739) Schizophr Res. 2013 Oct;150(1):3-10. (PMID: 23800613) Am J Psychiatry. 2002 Aug;159(8):1395-402. (PMID: 12153834) Int J Clin Pract. 2007 Aug;61(8):1356-70. (PMID: 17627711) Front Psychiatry. 2018 Apr 04;9:91. (PMID: 29670547) Am J Psychiatry. 2000 Jun;157(6):975-81. (PMID: 10831479) Diabetes Obes Metab. 2021 Feb;23(2):404-414. (PMID: 33074557) J Psychopharmacol. 2021 Sep;35(9):1111-1119. (PMID: 34311625) Open Med. 2009;3(3):e123-30. (PMID: 21603045) Early Interv Psychiatry. 2018 Oct;12(5):893-899. (PMID: 27734591) Psychol Med. 2022 Jul 12;:1-9. (PMID: 35818718) Diabetologia. 2016 May;59(5):954-65. (PMID: 26831302) J Neurochem. 2005 Feb;92(4):798-806. (PMID: 15686481) Lancet. 2007 Nov 17;370(9600):1706-13. (PMID: 18022033) Acta Psychiatr Scand. 2019 Jan;139(1):26-36. (PMID: 30374965) Lancet. 2013 Sep 14;382(9896):951-62. (PMID: 23810019) BMC Med. 2016 Nov 22;14(1):189. (PMID: 27871281) BMC Med. 2012 Aug 15;10:92. (PMID: 22891821) Am J Clin Nutr. 2012 Feb;95(2):297-308. (PMID: 22158731) Diabetes Obes Metab. 2021 Jun;23(6):1262-1271. (PMID: 33528914) Diabetes Obes Metab. 2019 Feb;21(2):293-302. (PMID: 30187620) JAMA. 2015 Aug 18;314(7):687-99. (PMID: 26284720) J Psychopharmacol. 2016 Mar;30(3):227-36. (PMID: 26801056) Diabetes Care. 2010 Jun;33(6):1173-5. (PMID: 20332357) Eur J Neurosci. 1995 Nov 1;7(11):2294-300. (PMID: 8563978) Trends Endocrinol Metab. 2022 Sep;33(9):628-638. (PMID: 35902330) Psychopharmacology (Berl). 2012 Jul;222(2):277-84. (PMID: 22274000) Front Pharmacol. 2018 Nov 28;9:1393. (PMID: 30546312) Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. (PMID: 28386912) Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. (PMID: 29221659) J Gen Physiol. 2008 Sep;132(3):329-38. (PMID: 18695009) Schizophr Res. 2012 Sep;140(1-3):159-68. (PMID: 22763424) J Clin Endocrinol Metab. 2015 Aug;100(8):2909-17. (PMID: 26043228) Curr Diab Rep. 2016 Feb;16(2):16. (PMID: 26803652) Front Psychiatry. 2019 Jan 28;9:781. (PMID: 30745885) Neuropharmacology. 2020 Jan 1;162:107813. (PMID: 31628935) JAMA Psychiatry. 2017 Jul 1;74(7):719-728. (PMID: 28601891) Diabetes Res Clin Pract. 2013 Jan;99(1):e3-4. (PMID: 23149376) World Psychiatry. 2019 Feb;18(1):53-66. (PMID: 30600626) CNS Drugs. 2007;21(2):129-41. (PMID: 17284095) Schizophr Res Cogn. 2014 Mar 1;1(1):e47-e52. (PMID: 25045625) Nat Rev Drug Discov. 2020 Apr;19(4):277-289. (PMID: 31848464) World Psychiatry. 2013 Oct;12(3):240-50. (PMID: 24096790) World Psychiatry. 2015 Jun;14(2):119-36. (PMID: 26043321) World Psychiatry. 2015 Oct;14(3):339-47. (PMID: 26407790) Neurobiol Aging. 2010 Sep;31(9):1495-502. (PMID: 18930564) Diabetes Obes Metab. 2017 Feb;19(2):162-171. (PMID: 27717222) Adv Ther. 2019 Jan;36(1):44-58. (PMID: 30465123) |
| فهرسة مساهمة: | Keywords: GLP-1 receptor agonists; meta-analysis; schizophrenia; systematic review; treatment |
| تواريخ الأحداث: | Date Created: 20230522 Latest Revision: 20230523 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10196269 |
| DOI: | 10.3389/fpsyt.2023.1153648 |
| PMID: | 37215670 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1664-0640 |
|---|---|
| DOI: | 10.3389/fpsyt.2023.1153648 |